JP7833477B2 - 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用 - Google Patents

血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用

Info

Publication number
JP7833477B2
JP7833477B2 JP2023557098A JP2023557098A JP7833477B2 JP 7833477 B2 JP7833477 B2 JP 7833477B2 JP 2023557098 A JP2023557098 A JP 2023557098A JP 2023557098 A JP2023557098 A JP 2023557098A JP 7833477 B2 JP7833477 B2 JP 7833477B2
Authority
JP
Japan
Prior art keywords
methyl
imidazo
pyridine
ethoxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023557098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510762A (ja
JP2024510762A5 (https=
JPWO2022194138A5 (https=
Inventor
チョウ，ディン
チェン，チーチャン
ワン，ヂェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zanrong Pharma Ltd
Original Assignee
Suzhou Zanrong Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Pharma Ltd filed Critical Suzhou Zanrong Pharma Ltd
Publication of JP2024510762A publication Critical patent/JP2024510762A/ja
Publication of JP2024510762A5 publication Critical patent/JP2024510762A5/ja
Publication of JPWO2022194138A5 publication Critical patent/JPWO2022194138A5/ja
Application granted granted Critical
Publication of JP7833477B2 publication Critical patent/JP7833477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
JP2023557098A 2021-03-17 2022-03-15 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用 Active JP7833477B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/081254 2021-03-17
PCT/CN2021/081254 WO2022193166A1 (en) 2021-03-17 2021-03-17 Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
PCT/CN2022/080905 WO2022194138A1 (en) 2021-03-17 2022-03-15 Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Publications (4)

Publication Number Publication Date
JP2024510762A JP2024510762A (ja) 2024-03-11
JP2024510762A5 JP2024510762A5 (https=) 2025-03-12
JPWO2022194138A5 JPWO2022194138A5 (https=) 2025-03-12
JP7833477B2 true JP7833477B2 (ja) 2026-03-19

Family

ID=83321678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557098A Active JP7833477B2 (ja) 2021-03-17 2022-03-15 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用

Country Status (8)

Country Link
US (1) US20240207263A1 (https=)
EP (1) EP4308569A4 (https=)
JP (1) JP7833477B2 (https=)
KR (1) KR20230157467A (https=)
CN (1) CN117412972A (https=)
AU (1) AU2021433713A1 (https=)
CA (1) CA3213823A1 (https=)
WO (2) WO2022193166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2020052688A1 (en) 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
BRPI0919932A8 (pt) 2008-10-24 2018-02-06 Novartis Ag Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína
NO2714752T3 (https=) 2014-05-08 2018-04-21
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2020052688A1 (en) 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF

Also Published As

Publication number Publication date
JP2024510762A (ja) 2024-03-11
KR20230157467A (ko) 2023-11-16
WO2022194138A1 (en) 2022-09-22
CA3213823A1 (en) 2022-09-22
EP4308569A1 (en) 2024-01-24
US20240207263A1 (en) 2024-06-27
EP4308569A4 (en) 2025-03-05
AU2021433713A1 (en) 2023-09-28
WO2022193166A1 (en) 2022-09-22
CN117412972A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JP7368369B2 (ja) Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
US20250122222A1 (en) Heterocyclic compounds and methods of use
EP4626555A1 (en) Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof
WO2024118960A1 (en) Glutarimide-containing kras-mutant degrader compounds and uses thereof
CN121368593A (zh) Kras抑制剂
JP7706585B2 (ja) 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
EP3416957A1 (en) 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
EP3546458A1 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
TW202417458A (zh) 調節her2的化合物及方法
JP7833477B2 (ja) 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
CA3015005C (en) 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2025155742A1 (en) Methods of use for quinazoline compounds
TW202602445A (zh) 作為ｋｒａｓ調節劑的螺環化合物及其用途
TW202602882A (zh) 作為ｋｒａｓ調節劑的大環化合物及其用途
TW202225163A (zh) 芳香雜環類化合物、藥物組合物及其應用
CN117940425A (zh) Her2突变抑制剂
HK40036499A (en) Heterocyclic compounds as prmt5 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260309

R150 Certificate of patent or registration of utility model

Ref document number: 7833477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150